Strategic Plan
2019 to 2024

International Pharmaceutical Federation (FIP)

Approved by the FIP Bureau, March 2019

Adopted by the FIP Council, September 2019
Colophon

Copyright 2019 International Pharmaceutical Federation (FIP)

International Pharmaceutical Federation (FIP)
Andries Bickerweg 5
2517 JP The Hague
The Netherlands
www.fip.org

All rights reserved. No part of this publication may be stored in any retrieval system or transcribed by any form or means – electronic, mechanical, recording, or otherwise without citation of the source. FIP shall not be held liable for any damages incurred resulting from the use of any data and information from this report. All measures have been taken to ensure accuracy of the data and information presented in this report.

Background and introduction

Purpose

The purpose of the Strategic Plan of the International Pharmaceutical Federation (FIP) is to:
Articulate the mission of FIP to the world and to key stakeholders to further strategic partnerships, purposeful collaborations and enhanced benefits for members and the profession;
Define the scope and guide the activities of the FIP for the next five years;
Maximise the strengths, mitigate weaknesses and threats, and take advantage of opportunities for growth that have been identified in the global healthcare environment;
Establish measures of success and demonstrate delivery for the benefit of members, member organisations, patients and the public.

Importance of consultation and engagement

The motivation for a renewed strategic plan was to enable FIP to increase its relevance and reach in recognition of the fast-changing landscape of pharmacy and healthcare, globally and within individual countries and healthcare systems.
FIP wanted and wants to engage and involve its member organisations, individual members and other key stakeholders in appraising and addressing the challenges that the profession, its partners, healthcare systems, and citizens will face in the years to come.

Strategic Planning Committee

Current Members, 2018:

Chair of the Committee Dr Carmen Pena, FIP President (Immediate Past President from September 2018)
Mr Israel Bimpe
Prof. William Charman
Ms Manjiri Gharat
Dr Linda Hakes
Mr Dominique Jordan (President from September 2018)
Prof. Ross McKinnon
Mr Thomas Menighan
Dr Miranda Sertić
Ms Ema Paulino, in her role as Interim CEO, and latterly Dr Catherine Duggan as CEO from June 2018

Other stakeholders

The FIP Bureau, FIP member organisations, FIP section presidents were involved in the consultation work.

Context

FIP has led the profession globally since 1912. During that time, the organisation has expanded and organised itself to include, represent and advocate for many types, sectors, sections across pharmacy, pharmacists and pharmaceutical science. Like all membership organisations, FIP must adapt to the demanding challenges facing the profession worldwide, in order to thrive.

❖

FIP has an opportunity to forge different relationship with its member organisations, to focus on the differing needs of regions and nations and ensure the advancement of healthcare in all parts of the world. FIP has an ideal opportunity
through collaboration with its member organisations to reflect experiences from all countries with advanced pharmacy practice and can focus and adapt to specific needs and conditions.

❖

By embracing advances in IT, automation, technology, genomics and biologicals, pharmacists and pharmaceutical scientists and educators can embrace new opportunities and grow their practice and science accordingly. Pharmacists will become medication managers by embracing new roles in primary care or filling other gaps in the healthcare system, while developing new practice and interdisciplinary models to enhance patient access to pharmaceutical care.

❖

FIP will work with others and set a new course for the pharmacy profession. FIP will increase flexibility and ensure efficient and effective governance in order to effect change in the broader health care environment. It is in the context of wider global change that FIP is setting a new vision, a new mission and strategic outcomes, as described in this document.

❖
Vision

Mission

Strategic Outcomes

Business Plan

Team plans and appraisals

The layout of the Strategic Plan

The Vision, the Mission and the six Strategic Outcomes agreed by the FIP Bureau and Council.

The Business Plan and associated team plans will be informed by the agreed strategy and will follow on an annual cycle.
Vision of the International Pharmaceutical Federation

A world where everyone benefits from access to safe, effective, quality and affordable medicines and health technologies, as well as from pharmaceutical care services provided by pharmacists, in collaboration with other healthcare professionals.

Mission of the International Pharmaceutical Federation

FIP supports global health by enabling the advancement of pharmaceutical practice, sciences and education.

FIP will:

- Advocate for the full utilisation of pharmacists’ expertise for the benefit of people and healthcare systems;
- Promote pharmacy as the first point of access for pharmaceutical care for every person in the world;
- Support and strengthen the integrity of the pharmaceutical supply chain from manufacturing to patient access;
- Improve health outcomes by the development and implementation of pharmacy services;
- Support the science-based development and regulation of medicines and health technologies to meet healthcare needs;
- Support pharmaceutical workforce development around the world to deliver our vision;
- Collaborate with international agencies, partners, and other healthcare professions, to ensure comprehensive and integrated health care for all.
FIP will collaborate with all its members and observers to maximise the global influence and contributions to healthcare of pharmacists, pharmaceutical scientists and pharmacy educators. FIP commits to strive for the following six strategic outcomes to be achieved:

**Strategic Outcome #1**

**Everyone has access to the medicines they need.**

**FIP will:**

1.1 Advocate for everyone to have access to the medicines they need in accordance with the principles of Universal Health Coverage\(^1\).
1.2 Collaborate with global and international agencies and partners to work to eliminate medicine shortages, sub-standard and falsified medicines.
1.3 Collaborate with global and international agencies to ensure access and affordability to essential medicines.

**Strategic Outcome #2**

**Everyone has access to the health and medicines-related information they need.**

**FIP will:**

2.1 Provide leadership and support to pharmacists to ensure people have the information they need and value about medicines and services, in order to derive the maximum benefit from them.
2.2 Provide leadership and support to pharmacists to empower people to take better care of themselves, through prevention strategies and health promotion.
2.3 Collaborate to create and sustain policies and practices that support each person to make informed choices in areas such as medication adherence.

**Strategic Outcome #3**

**Everyone benefits from innovations in medicines, health technologies and services.**

**FIP will:**

3.1 Support the discovery, development and innovations in medicines, health technologies, and services.
3.2 Work with member organisations and partners to set usable standards in areas of pharmaceutical care, science, research and education.
3.3 Enable sustainable pharmacy services to ensure the responsible use of innovations in medicines, with appropriate remuneration.

\(^1\) Universal health coverage (UHC) is defined as ensuring that all people have access to needed health services (including prevention, promotion, treatment, rehabilitation and palliation) of sufficient quality to be effective while also ensuring that the use of these services does not expose the user the financial hardship. Universal health coverage has therefore become a major goal for health reform in many countries and a priority objective of WHO.
Strategic Outcome #4

Pharmacists ensure the responsible and quality use of medicines.

FIP will:

4.1 Support and empower pharmacists to provide high quality person-centred pharmaceutical care to improve health outcomes for individuals and populations alike.
4.2 Set standards and advocate for sustainable pharmaceutical care services which ensure the responsible use of medicines.
4.3 Work to reduce the abuse and misuse of medicines to ensure patient safety and public benefit.

Strategic Outcome #5

Work collaboratively to ensure comprehensive and integrated healthcare outcomes for patients.

FIP will:

5.1 Establish strategic partnerships across international agencies and organisations to achieve shared outcomes for the benefit of patients and the public.
5.2 Work in partnership with patient organisations to align pharmacy services with patient needs.
5.3 Promote the responsible use of limited healthcare resources by helping people stay healthy, reducing unnecessary use of medicines, and preventing adverse drug events.
5.4 Collaborate with relevant organisations on shared projects to deliver improved health benefits and public health for all.

Strategic Outcome #6

FIP is a cost-effective, unified, vibrant and growing organisation that meets the needs and supports the work of its members.

FIP will:

6.1 Focus on our members in all that we do.
6.2 Develop future leaders from all parts of the organisation, the profession and the globe.
6.3 Facilitate and enable the sharing of relevant knowledge and professional development tools for all members, across countries and regions.
6.4 Improve decision-making processes and models for developing business to ensure FIP continues to grow and develop.